Sagimet Biosciences Inc. Operating Income
Sagimet Biosciences Inc. (SGMT) reported Operating Income of -$15.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Sagimet Biosciences Inc. operating income (loss) for the quarter ending 2026-06-30 was -$15.82M.
- Sagimet Biosciences Inc. operating income (loss) for the quarter ending 2026-03-31 was -$11.71M.
- Sagimet Biosciences Inc. operating income (loss) for the quarter ending 2025-12-31 was -$10.77M.
- Sagimet Biosciences Inc. operating income (loss) for the quarter ending 2025-09-30 was -$14.33M.
- Sagimet Biosciences Inc. operating income (loss) for fiscal 2025 was -$56.89M.
- Sagimet Biosciences Inc. operating income (loss) for fiscal 2024 was -$54.45M.
- Sagimet Biosciences Inc. operating income (loss) for fiscal 2023 was -$30.74M.
- Sagimet Biosciences Inc. operating income (loss) for fiscal 2022 was -$31.05M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.82M 10-Q · filed 2026-08-11 | -$27.53M 10-Q · filed 2026-08-11 | -$38.30M derived: sum of 3 quarters · filed 2026-08-11 | -$52.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$11.71M 10-Q · filed 2026-05-12 | -$22.48M derived: sum of 2 quarters · filed 2026-05-12 | -$36.81M derived: sum of 3 quarters · filed 2026-05-12 | -$48.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$25.10M derived: sum of 2 quarters · filed 2026-03-11 | -$37.02M derived: sum of 3 quarters · filed 2026-08-11 | -$56.89M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$14.33M 10-Q · filed 2025-11-13 | -$26.26M derived: sum of 2 quarters · filed 2026-08-11 | -$46.12M 10-Q · filed 2025-11-13 | -$64.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$11.93M 10-Q · filed 2026-08-11 | -$31.79M 10-Q · filed 2026-08-11 | -$49.98M derived: sum of 3 quarters · filed 2026-08-11 | -$66.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$19.86M 10-Q · filed 2026-05-12 | -$38.06M derived: sum of 2 quarters · filed 2026-05-12 | -$54.96M derived: sum of 3 quarters · filed 2026-05-12 | -$65.55M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$18.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$35.10M derived: sum of 2 quarters · filed 2026-03-11 | -$45.69M derived: sum of 3 quarters · filed 2026-03-11 | -$54.45M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$16.90M 10-Q · filed 2025-11-13 | -$27.49M derived: sum of 2 quarters · filed 2025-11-13 | -$36.26M 10-Q · filed 2025-11-13 | -$45.73M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$10.59M 10-Q · filed 2025-08-13 | -$19.36M 10-Q · filed 2025-08-13 | -$28.82M derived: sum of 3 quarters · filed 2025-08-13 | -$36.27M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$8.77M 10-Q · filed 2025-05-08 | -$18.23M derived: sum of 2 quarters · filed 2025-05-08 | -$25.69M derived: sum of 3 quarters · filed 2025-05-08 | -$32.74M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$9.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$16.92M derived: sum of 2 quarters · filed 2025-03-12 | -$23.98M derived: sum of 3 quarters · filed 2025-03-12 | -$30.74M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$7.45M 10-Q · filed 2024-11-14 | -$14.51M derived: sum of 2 quarters · filed 2024-11-14 | -$21.27M 10-Q · filed 2024-11-14 | -$28.66M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$7.06M 10-Q · filed 2024-08-14 | -$13.82M 10-Q · filed 2024-08-14 | -$21.21M derived: sum of 3 quarters · filed 2024-08-14 | -$28.90M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$6.76M 10-Q · filed 2024-05-15 | -$14.15M derived: sum of 2 quarters · filed 2024-05-15 | -$21.84M derived: sum of 3 quarters · filed 2024-05-15 | -$29.08M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$15.07M derived: sum of 2 quarters · filed 2024-03-25 | -$22.31M derived: sum of 3 quarters · filed 2024-03-25 | -$31.05M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$7.69M 10-Q · filed 2023-11-13 | -$14.92M derived: sum of 2 quarters · filed 2023-11-13 | -$23.67M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$7.24M 10-Q · filed 2023-08-21 | -$15.98M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |